XBIO · Xenetic Biosciences, Inc.

Xenetic Biosciences’ Q1 2026 financial results reflect operational discipline and progress on its core DNase I oncology platform. Royalty revenue rose 36% year-over-year to $0.8 million, explicitly attributed to increased payments under the sublicense agreement with Takeda Pharmaceuticals Co. Ltd., indicating continued monetization of legacy assets. R&D expenses fell 25% to $0.7 million, primarily due to reduced preclinical and exploratory study costs — though this decline was partially offset by increased investment in manufacturing development for the DNase I program, signaling prioritization of clinical readiness. G&A expenses edged down 1.4% to $0.6 million, with personnel and share-based compensation savings largely counterbalanced by higher legal expenses tied to the Board’s ongoing strategic review process. The resulting net loss of $0.5 million represents a 49% improvement over the prior-year quarter’s $0.9 million loss, underscoring improved cost management amid stable non-dilutive revenue. Cash stood at $7.3 million as of March 31, 2026 — a $0.6 million reduction from $7.9 million at year-end — consistent with sustained R&D and strategic review expenditures. Management emphasized translational data generation, analytical process improvements, biomarker insights, and the initiation of an investigator-led study in Israel combining DNase I with anti-CD19 CAR T cells — all aimed at de-risking future clinical trial design. With no forward-looking financial guidance disclosed in Exhibit 99.1 or the 8-K body, investors must interpret the 49% net loss reduction and platform advancement as evidence of near-term execution capability, while recognizing that long-term value hinges on successful clinical translation and resolution of the strategic review process, which remains explicitly open-ended and subject to market, regulatory, and timing risks.